A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo
Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2017-09 · 3 (3)
DOI: 10.1177/2055217317730096 ↗Kurz gefasst
Fachartikel in der Zeitschrift Multiple Sclerosis Journal - Experimental, Translational and Clinical, online erschienen am 27.09.2017. Verfasst von Patrick Vermersch und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Lille, CHU Lille, LIRIC - INSERM U995, FHU Imminent, France. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Cases of higher-than-expected disease activity have been reported following fingolimod discontinuation.
Objective
The objective of this paper is to assess the risk of substantially higher-than-expected disease activity post-study drug discontinuation (SDD) at the individual patient level using data from the Phase III, placebo-controlled FREEDOMS and FREEDOMS II trials.
Methods
Baseline gadolinium-enhancing T1-lesion volumes were used to statistically model the expected level of MRI disease activity post-SDD. Patients exceeding this level were classed as “MRI outliers.” Patients with an unusually high increase in Expanded Disability Status Scale score, hospitalization for relapse, severe relapse, or relapse with incomplete recovery post-SDD were classed as “clinical outliers.” Results In FREEDOMS, the number of MRI outliers post-SDD was 2/69 (2.9%), 1/65 (1.5%) and 7/83 (8.4%) for the placebo, fingolimod 0.5 mg, and fingolimod 1.25 mg groups, respectively. In FREEDOMS II, the corresponding numbers were 4/72 (5.6%), 6/79 (7.6%) and 3/73 (4.1%). The number of clinical outliers across both trials was low. No consistent evidence of placebo vs fingolimod, dose-related or inter-trial patterns was discernable.
Conclusion
The low number of clinical and MRI outliers and lack of any discernible pattern within and between trials, including between placebo and fingolimod, argues against a systematic risk of higher-than-expected recurrence of disease activity following discontinuation of fingolimod.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Lille, CHU Lille, LIRIC - INSERM U995, FHU Imminent, France.
- Medical Image Analysis Center, University Hospital Basel, Switzerland.
- Novartis Pharmaceuticals Corporation, USA.
- Novartis Pharma AG, Switzerland.
- University of Ottawa, The Ottawa Hospital Research Institute, Canada.
Zitieren
APA
Vermersch, P., Radue, E. W., Putzki, N., Ritter, S., Merschhemke, M., & Freedman, M. S. (2017). A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 3(3). https://doi.org/10.1177/2055217317730096
Vancouver
Vermersch P, Radue EW, Putzki N, Ritter S, Merschhemke M, Freedman MS. A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Multiple Sclerosis Journal - Experimental, Translational and Clinical. 2017;3(3). doi:10.1177/2055217317730096
BibTeX
@article{Vermersch2017,
author = {Vermersch, Patrick and Radue, Ernst-Wilhelm and Putzki, Norman and Ritter, Shannon and Merschhemke, Martin and Freedman, Mark S},
title = {A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo},
journal = {Multiple Sclerosis Journal - Experimental, Translational and Clinical},
year = {2017},
volume = {3},
number = {3},
doi = {10.1177/2055217317730096}
}
EUVIMED